Search: id:"swepub:oai:lup.lub.lu.se:9ba961e8-d371-4a9c-93f9-0590a426763b" >
The estrogen recept...
-
Narbe, UlrikLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups,Växjö Central Hospital
(author)
The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
- Article/chapterEnglish2019
Publisher, publication year, extent ...
-
2019-02-22
-
Springer Science and Business Media LLC,2019
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:9ba961e8-d371-4a9c-93f9-0590a426763b
-
https://lup.lub.lu.se/record/9ba961e8-d371-4a9c-93f9-0590a426763bURI
-
https://doi.org/10.1007/s10549-019-05138-7DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
Purpose: According to the 2017 St Gallen surrogate definitions of the intrinsic subtypes, Ki67, progesterone receptor (PR) and Nottingham histological grade (NHG) are used for prognostic classification of estrogen receptor (ER) positive/HER2-negative breast cancer into luminal A- or luminal B-like. The aim of the present study was to investigate if additional biomarkers, related to endocrine signaling pathways, e.g., amplified in breast cancer 1 (AIB1), androgen receptor (AR), and G protein-coupled estrogen receptor (GPER), can provide complementary prognostic information in a subset of ER-positive/HER-negative invasive lobular carcinoma (ILC). Methods: Biomarkers from 224 patients were analyzed immunohistochemically on tissue microarray. The primary endpoint was breast cancer mortality (BCM), analyzed with 10- and 25-year follow-up (FU). In addition, the prognostic value of gene expression data for these biomarkers was analyzed in three publicly available ILC datasets. Results: AIB1 (high vs. low) was associated to BCM in multivariable analysis (adjusted for age, tumor size, nodal status, NHG, Ki67, luminal-like classification, and adjuvant systemic therapy) with 10-year FU (HR 6.8, 95% CI 2.3–20, P = 0.001) and 25-year FU (HR 3.0, 95% CI 1.1–7.8, P = 0.03). The evidence of a prognostic effect of AIB1 could be confirmed by linking gene expression data to outcome in independent publicly available ILC datasets. AR and GPER were neither associated to BCM with 10-year nor with 25-year FU (P > 0.33). Furthermore, Ki67 and NHG were prognostic for BCM at both 10-year and 25-year FU, whereas PR was not. Conclusions: AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative ILC.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sjöström, MartinLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups(Swepub:lu)med-msm
(author)
-
Forsare, CarinaLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups(Swepub:lu)onk-cst
(author)
-
Bendahl, Pär OlaLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups(Swepub:lu)onk-pbe
(author)
-
Alkner, SaraLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups,Skåne University Hospital(Swepub:lu)med-srt
(author)
-
Leeb-Lundberg, L. M.FredrikLund University,Lunds universitet,Drug Target Discovery,Forskargrupper vid Lunds universitet,Lund University Research Groups(Swepub:lu)mphy-fle
(author)
-
Lövgren, KristinaLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups(Swepub:lu)onk-klo
(author)
-
Rydén, LisaLund University,Lunds universitet,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Breast Cancer Surgery,Lund University Research Groups,Skåne University Hospital(Swepub:lu)pat-lry
(author)
-
Ingvar, ChristianLund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)kir-cin
(author)
-
Fernö, MårtenLund University,Lunds universitet,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Personalized Breast Cancer Treatment,Lund University Research Groups(Swepub:lu)onk-mfe
(author)
-
Individuell BröstcancerbehandlingForskargrupper vid Lunds universitet
(creator_code:org_t)
Related titles
-
In:Breast Cancer Research and Treatment: Springer Science and Business Media LLC175:2, s. 305-3160167-68061573-7217
Internet link
Find in a library
To the university's database
- By the author/editor
-
Narbe, Ulrik
-
Sjöström, Martin
-
Forsare, Carina
-
Bendahl, Pär Ola
-
Alkner, Sara
-
Leeb-Lundberg, L ...
-
show more...
-
Lövgren, Kristin ...
-
Rydén, Lisa
-
Ingvar, Christia ...
-
Fernö, Mårten
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Breast Cancer Re ...
- By the university
-
Lund University